You just read:

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

News provided by

Eiger BioPharmaceuticals, Inc.

Jul 18, 2016, 08:00 ET